title: [Treatment of hyperandrogenic manifestations in polycystic ovary syndrome].
abstract: Etiopathogenesis of the polycystic ovarian disease is not clarified. Therefore, optimum therapy of hyperandrogenic syndromes, menstrual and fertility disorders pose a difficult problem. Sequential therapy with estrogens and progestagens is of value in young women, who are not planning to conceive in order to reduce hirsutism and regulate menses. A reduction of hirsutism, acne and seborrhea is produced within 3 months. However, cessation of the treatment produces the symptoms of excessive androgen production. Another method is therapy with antiandrogens, especially cyproterone acetate. This drug inhibits androgens biosynthesis and has also peripheral activity. Spironolactone is another antiandrogen frequently used, but it is known as a primarily diuretic agent. It acts primarily at the androgen receptor sites. Other antiandrogens such as ketoconazole and flutamide are used less frequently. It has been shown, that cimetidine--known H2 receptor inhibitor--also decreases the symptoms of hyperandrogenism. However, cimetidine has not been used for the treatment of polycystic ovarian disease. In cases of enzymatic defects in adrenocortical steroido-synthesis glucocorticoids are used, mainly low doses of triamcinolone and dexamethasone. Other therapies are preferred in case of polycystic ovarian disease in women, who want to conceive. Clomiphene citrate and gonadotropins, mainly FSH, are used to induce ovulation. If pharmacotherapy does not produce ovulation, wedge resection of the ovaries must be performed.
authors.affiliation: Katedry i Kliniki Endokrynologii AM, Wrocławiu.
authors.forename: G
authors.initials: G
authors.lastname: Bednarek-Tupikowska
authors.forename: A
authors.initials: A
authors.lastname: Milewicz
authors.forename: A
authors.initials: A
authors.lastname: Bohdanowicz-Pawlak
authors.forename: B
authors.initials: B
authors.lastname: Bidzińska
authors.forename: J
authors.initials: J
authors.lastname: Szymczak
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D005260:Female; D006628:Hirsutism / Q000188:drug therapy; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D017588:Hyperandrogenism / Q000209:etiology / Q000628:therapy*; D008599:Menstruation Disturbances / Q000188:drug therapy; D011085:Polycystic Ovary Syndrome / Q000150:complications*
chemical_list: D000726:Androgen Antagonists; D006728:Hormones
vernacular_title: Leczenie objawów hiperandrogenizmu w zespole wielotorbielowatych jajników.